title: A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder.
abstract: BACKGROUND
  Both psychodynamic group therapy (PGT) and clonazepam are used as treatment strategies in reducing symptoms of generalized social anxiety disorder (GSAD). However, many individuals remain symptomatic after treatment with PGT or clonazepam.
  
  
  METHODS
  Fifty-eight adult outpatients with a diagnosis of GSAD according to DSM-IV were randomized to 12 weeks PGT plus clonazepam or clonazepam. The Clinical Global Impression-Improvement (CGI-I) Scale was the primary efficacy measure. Secondary efficacy measures included the Liebowitz Social Anxiety Scale (LSAS) total score, the World Health Organization Instrument to Assess Quality of Life-Brief (WHOQOL-Bref) Scale and the Beck Depression Inventory (BDI).
  
  
  RESULTS
  CGI-I data from 57 patients (intent-to-treat population) showed that patients who received PGT plus clonazepam presented significantly greater improvement than those who received clonazepam (P=0.033). There were no significant differences between the two groups in the secondary efficacy measures.
  
  
  CONCLUSIONS
  Our study suggests that the combination of PGT with clonazepam may be a promising strategy for the treatment of GSAD, regarding gains in the global functioning. However the present study failed to detect more specific changes in social anxiety symptomatology between the two groups.
authors.affiliation: Psychiatry, School of Medicine, Universidade Federal do Rio Grande do Sul and Anxiety Disorders Program, Hospital de Clínicas de Porto Alegre, Ramiro Barcellos 2350, room 400N, CEP 90035-003, Porto Alegre, RS, Brazil. knijnikd@terra.com.br
authors.forename: Daniela Z
authors.initials: DZ
authors.lastname: Knijnik
authors.forename: Carlos
authors.initials: C
authors.lastname: Blanco
authors.forename: Giovanni Abrahão
authors.initials: GA
authors.lastname: Salum
authors.forename: Carolina U
authors.initials: CU
authors.lastname: Moraes
authors.forename: Clarissa
authors.initials: C
authors.lastname: Mombach
authors.forename: Ellen
authors.initials: E
authors.lastname: Almeida
authors.forename: Marília
authors.initials: M
authors.lastname: Pereira
authors.forename: Atahualpa
authors.initials: A
authors.lastname: Strapasson
authors.forename: Gisele G
authors.initials: GG
authors.lastname: Manfro
authors.forename: Cláudio L
authors.initials: CL
authors.lastname: Eizirik
mesh_terms: D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002998:Clonazepam / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009769:Object Attachment; D010552:Personality Assessment; D010698:Phobic Disorders / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D010865:Pilot Projects; D011575:Psychoanalytic Therapy; D011615:Psychotherapy, Group; D055815:Young Adult
chemical_list: D014151:Anti-Anxiety Agents; D002998:Clonazepam
references.citation: Psychiatr Clin North Am. 2001 Dec;24(4):817-29
references.pmid: 11723635
references.citation: Arch Gen Psychiatry. 1998 Dec;55(12):1133-41
references.pmid: 9862558
references.citation: Bull Menninger Clin. 2005 Winter;69(1):1-58
references.pmid: 15899755
references.citation: Can J Psychiatry. 2005 May;50(6):308-16
references.pmid: 15999944
references.citation: Int J Neuropsychopharmacol. 2001 Sep;4(3):279-98
references.pmid: 11602035
references.citation: N Engl J Med. 2006 Sep 7;355(10):1029-36
references.pmid: 16957148
references.citation: Psychopharmacol Bull. 1998;34(2):169-74
references.pmid: 9640996
references.citation: Behav Res Ther. 2002 Jun;40(6):701-15
references.pmid: 12051488
references.citation: Am J Psychother. 2006;60(3):233-59
references.pmid: 17066756
references.citation: J Clin Psychiatry. 2004 Feb;65(2):244-8
references.pmid: 15003080
references.citation: Depress Anxiety. 2003;18(1):29-40
references.pmid: 12900950
references.citation: Am J Psychiatry. 2007 Feb;164(2):265-72
references.pmid: 17267789
references.citation: J Pers Disord. 2003 Dec;17(6):510-21
references.pmid: 14744077
references.citation: Rev Saude Publica. 2000 Apr;34(2):178-83
references.pmid: 10881154
references.citation: Arch Gen Psychiatry. 1961 Jun;4:561-71
references.pmid: 13688369
references.citation: J Clin Psychopharmacol. 2001 Jun;21(3):311-24
references.pmid: 11386495
references.citation: Clin Psychol Rev. 2004 Nov;24(7):883-908
references.pmid: 15501560
references.citation: Arch Gen Psychiatry. 2004 Oct;61(10):1005-13
references.pmid: 15466674
references.citation: Can J Psychiatry. 1987 Mar;32(2):153-5
references.pmid: 3567825
references.citation: Behav Modif. 1998 Jul;22(3):285-97
references.pmid: 9670801
references.citation: JAMA. 2000 May 17;283(19):2529-36
references.pmid: 10815116
references.citation: J Anxiety Disord. 2000 Jul-Aug;14(4):345-58
references.pmid: 11043885
references.citation: Braz J Psychiatry. 2004 Jun;26(2):77-81
references.pmid: 15517057
references.citation: Nord J Psychiatry. 2001;55(6):419-25
references.pmid: 11839136
references.citation: J Affect Disord. 1998 Sep;50 Suppl 1:S17-22
references.pmid: 9851574
references.citation: J Clin Psychiatry. 2005 Feb;66(2):238-47
references.pmid: 15705011
references.citation: J Clin Psychopharmacol. 1993 Dec;13(6):423-8
references.pmid: 8120156
references.citation: Arch Gen Psychiatry. 2004 Dec;61(12):1208-16
references.pmid: 15583112
references.citation: Int J Psychoanal. 2005 Jun;86(Pt 3):841-68
references.pmid: 16096078
references.citation: Am J Psychiatry. 2005 Jan;162(1):151-61
references.pmid: 15625214
references.citation: Int J Group Psychother. 2004 Oct;54(4):491-519
references.pmid: 15388403
references.citation: J Clin Psychopharmacol. 1998 Dec;18(6):429-34
references.pmid: 9864073
references.citation: Depress Anxiety. 2008;25(6):542-53
references.pmid: 17941096
references.citation: Arch Gen Psychiatry. 1987 Mar;44(3):259-64
references.pmid: 3548638
references.citation: Hosp Community Psychiatry. 1983 Dec;34(12):1111-7
references.pmid: 6642457
references.citation: Bull Menninger Clin. 1994 Spring;58(2 Suppl A):A3-20
references.pmid: 8044136
references.citation: Perspect Psychiatr Care. 2002 Jul-Sep;38(3):89-97
references.pmid: 12385079
references.citation: J Clin Psychiatry. 1991 Nov;52 Suppl:16-20
references.pmid: 1757453
references.citation: J Clin Psychiatry. 2006;67 Suppl 12:20-6
references.pmid: 17092192
references.citation: Acta Psychiatr Scand Suppl. 2003;(417):72-84
references.pmid: 12950438
references.citation: Psychol Med. 2001 Aug;31(6):1025-35
references.pmid: 11513370
references.citation: J Clin Psychopharmacol. 1998 Oct;18(5):373-8
references.pmid: 9790154
references.citation: Mod Probl Pharmacopsychiatry. 1987;22:141-73
references.pmid: 2885745
references.citation: J Clin Psychiatry. 2005 Apr;66(4):455-68
references.pmid: 15816788
references.citation: Int J Psychoanal. 2000 Jun;81 ( Pt 3):513-27
references.pmid: 10967773
references.citation: N Engl J Med. 2000 May 18;342(20):1462-70
references.pmid: 10816183
references.citation: Bull Menninger Clin. 1992 Spring;56(2 Suppl A):A3-13
references.pmid: 1623339